Immune Therapeutics, Inc. , a clinical-stage company developing novel therapies for the treatment of immuno-inflammatory diseases and cancer, today announced it has further strengthened its balance sheet through the refinancing of its largest remaining convertible debenture of $321,846 – in full. By redeeming that debenture and refinancing it with debt at more favorable terms – by one institutional investor who is favorably inclined toward IMUN’s fundamentals – the Company is one step closer towards positive cash flow.